Details:
Under the agreement, Global Biopharmaceutical will Leverage Biorchestra Targeting Technology Platform, BDDS™ to Develop Nucleic Acid Therapies, including BMD-001, for Treatment of Neurological Disorders in Multiple Targets.
Lead Product(s): BMD-001
Therapeutic Area: Neurology Product Name: BMD-001
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $861.0 million Upfront Cash: Undisclosed
Deal Type: Agreement March 27, 2023
Details:
BMD-001 (or BDDS : miR-485-3p ASO) is an antisense oligonucleotides encapsulated with proprietary Brin polymer to cross blood-brain barrier and plasma membrane of microglia, astrocyte and neuron to degrade the microRNA 485-3p and treat neuroinflammation and neurodegeneration.
Lead Product(s): BMD-001
Therapeutic Area: Neurology Product Name: BMD-001
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
SNR1611 is drug candidate that has been repurposed for neurodegenerative disease from a previously FDA-approved anti-cancer drug, has already confirmed SNR1611’s effect on neuron regeneration and functional recovery through preclinical research.
Lead Product(s): SNR1611
Therapeutic Area: Neurology Product Name: SNR1611
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Details:
Under the terms of the agreement, Neuramedy has obtained worldwide rights to research, develop and commercialize an xB3TM version of its antibody, Tomaralimab, directed at the Toll-like receptor 2.
Lead Product(s): Tomaralimab
Therapeutic Area: Neurology Product Name: NM-101
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Bioasis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 10, 2022
Details:
The agreement covers process development for ANLBIO’s gene therapy vector, ANL-101, followed by 200 L scale production. The manufacturing part of the agreement covers upscaling of the process to working volume of 100s of liters and subsequent manufacture facilities.
Lead Product(s): ANL-101
Therapeutic Area: Neurology Product Name: ANL-101
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Biovian
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 18, 2022
Details:
ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease.
Lead Product(s): ABL301
Therapeutic Area: Neurology Product Name: ABL301
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $1,060.0 million Upfront Cash: $75.0 million
Deal Type: Collaboration January 11, 2022